The global blood cancer diagnostics market size is calculated at USD 11.65 billion for 2025 and is forecasted to reach around USD 21.24 billion by 2034, accelerating at a CAGR of 6.90% from 2025 to 2034. The North America market size surpassed USD 5.01 billion in 2024 and is expanding at a CAGR of 7.02% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Blood Cancer Diagnostics Industry Impact
5.2. COVID-19 Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Blood Cancer Diagnostics Market, by Product
8.1.1 Instruments
8.1.1.1. Market Revenue and Forecast
8.1.2. Assay Kits and Reagents
8.1.2.1. Market Revenue and Forecast
9.1. Blood Cancer Diagnostics Market, by Test
9.1.1. Blood Tests
9.1.1.1. Market Revenue and Forecast
9.1.2. Imaging Tests
9.1.2.1. Market Revenue and Forecast
9.1.3. Biopsy
9.1.3.1. Market Revenue and Forecast
9.1.4. Molecular Test
9.1.4.1. Market Revenue and Forecast
10.1. Blood Cancer Diagnostics Market, by End Use
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Diagnostic Labs
10.1.2.1. Market Revenue and Forecast
10.1.3. Research Institutes
10.1.3.1. Market Revenue and Forecast
10.1.4. Cheese
10.1.4.1. Market Revenue and Forecast
10.1.5. Others
10.1.5.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product
11.1.2. Market Revenue and Forecast, by Test
11.1.3. Market Revenue and Forecast, by End Use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product
11.1.4.2. Market Revenue and Forecast, by Test
11.1.4.3. Market Revenue and Forecast, by End Use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product
11.1.5.2. Market Revenue and Forecast, by Test
11.1.5.3. Market Revenue and Forecast, by End Use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product
11.2.2. Market Revenue and Forecast, by Test
11.2.3. Market Revenue and Forecast, by End Use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product
11.2.4.2. Market Revenue and Forecast, by Test
11.2.4.3. Market Revenue and Forecast, by End Use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product
11.2.5.2. Market Revenue and Forecast, by Test
11.2.5.3. Market Revenue and Forecast, by End Use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product
11.2.6.2. Market Revenue and Forecast, by Test
11.2.6.3. Market Revenue and Forecast, by End Use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product
11.2.7.2. Market Revenue and Forecast, by Test
11.2.7.3. Market Revenue and Forecast, by End Use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product
11.3.2. Market Revenue and Forecast, by Test
11.3.3. Market Revenue and Forecast, by End Use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product
11.3.4.2. Market Revenue and Forecast, by Test
11.3.4.3. Market Revenue and Forecast, by End Use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product
11.3.5.2. Market Revenue and Forecast, by Test
11.3.5.3. Market Revenue and Forecast, by End Use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product
11.3.6.2. Market Revenue and Forecast, by Test
11.3.6.3. Market Revenue and Forecast, by End Use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product
11.3.7.2. Market Revenue and Forecast, by Test
11.3.7.3. Market Revenue and Forecast, by End Use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product
11.4.2. Market Revenue and Forecast, by Test
11.4.3. Market Revenue and Forecast, by End Use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product
11.4.4.2. Market Revenue and Forecast, by Test
11.4.4.3. Market Revenue and Forecast, by End Use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product
11.4.5.2. Market Revenue and Forecast, by Test
11.4.5.3. Market Revenue and Forecast, by End Use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product
11.4.6.2. Market Revenue and Forecast, by Test
11.4.6.3. Market Revenue and Forecast, by End Use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product
11.4.7.2. Market Revenue and Forecast, by Test
11.4.7.3. Market Revenue and Forecast, by End Use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product
11.5.2. Market Revenue and Forecast, by Test
11.5.3. Market Revenue and Forecast, by End Use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product
11.5.4.2. Market Revenue and Forecast, by Test
11.5.4.3. Market Revenue and Forecast, by End Use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product
11.5.5.2. Market Revenue and Forecast, by Test
11.5.5.3. Market Revenue and Forecast, by End Use
12.1. Illumina
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. InVivoScribe
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Ipsogen (Qiagen)
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Asuragen(Bio-Techne)
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Thermo Fisher Scientific Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Danaher Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Abbott
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sequenta (Adaptive Biotechnologies)
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SkylineDx,
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bio-Rad Laboratories
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample